Consensus has yet to emerge regarding the optimal choice of therapy in the management of malignant pericardial effusion. We review the literature to evaluate the existing evidence on the clinical effectiveness of surgical and interventional cardiological approaches. A formal literature search for all studies addressing the treatment of pericardial effusion in cancer patients was undertaken using predefined keywords. Abstracts were screened and reviewed, and data extracted. Data on intervention type, number of patients treated, number of patients surviving the procedure, effusion recurrences, need for further interventions and procedure-related complications were obtained from each study and collated in a quantitative synthesis. Of 1181 articles identified, 59 contained sufficient quantitative information to be included in the synthesis. A total of 2322 patients with symptomatic pericardial effusion were identified, of which 1399 patients were reported to have underlying malignancy. Three surgical approaches were described in a total of 19 studies, with overall success rates ranging from 93.3 to 100% and associated complication rates ranging from 4.5 to 10.3%. The remaining 40 studies reported four non-surgical treatment modalities, with success rates of 55.1-90.4% and complication rates of 5.9-32%. Data from the literature suggest that surgical drainage of the pericardium is superior to non-surgical approaches for symptom relief, effusion recurrence and morbidity; however, the lack of randomized controlled trials means that selection bias remains an important limitation to the field and definitive adequately controlled trials should be a priority.
INTRODUCTION
The pericardium is a frequent site for neoplastic involvement [1] . Although primary tumours of the pericardium are rare, metastases to the heart and pericardium have been reported in up to 21% of cancer patients [2] . The majority of these patients remain asymptomatic, but impairment of cardiac function contributing to morbidity occurs in one-third of cases [3] . Moreover, the potential for life-threatening cardiac tamponade makes pericardial effusion an important contributor to mortality in cancer patients and can require emergency decompression.
Despite aggressive treatment, the prognosis for patients with malignant pericardial effusion remains poor and is primarily dictated by the underlying disease [4] . Therefore, goal of treatment is palliation of symptoms and prevention of effusion recurrence; however, the 'gold standard' treatment for malignant pericardial effusion has yet to be defined. Although simple pericardiocentesis is effective in the emergency setting of cardiac tamponade, rapid reaccumulation of pericardial fluid commonly occurs unless more definitive measures are used [5] .
Current guidelines recommend several approaches, both interventional cardiological and surgical; however, no randomized controlled trials have been undertaken to determine the relative merits of these treatment modalities [6] . Given that this subject was reviewed previously, several studies have been published but a consensus has yet to emerge regarding the optimal therapeutic strategy [7] [8] [9] . In this systematic review, we set out to address the following question: in patients with malignant pericardial effusion, is surgical treatment superior to interventional cardiological management in terms of resolution of symptoms and prevention of effusion recurrence?
MATERIALS AND METHODS

Sources of data
We searched Embase from 1974 to May 2013, Medline from 1946 to May 2013 and the Cochrane Library database in May 2013 using a formal search strategy. Combinations of predefined Medical Subject Heading (MeSH) terms and text words related to the treatment of pericardial effusion in cancer patients were used. The search was conservative to retain any likely contributing studies; however, publications in foreign languages were excluded.
In addition, we searched the reference lists of publications to identify additional studies of relevance.
Eligibility criteria
Publications describing the outcomes of patients diagnosed with malignant pericardial effusion by imaging or cytology were considered. Our literature search identified several studies reporting mixed patient groups with both neoplastic and non-malignant pericardial effusions. In such cases, data extraction was deemed possible only if the outcomes of patients undergoing treatment for malignant pericardial effusion were reported separately. Studies were included only if they reported outcomes for a single common treatment modality rather than combinations of treatment (Table 1) .
Data extraction
Results from the online search were imported into a reference management program for the detection of duplicates. Next, studies were grouped on a spreadsheet for further analysis. For each study, intervention type, number of patients treated, number of patients surviving the procedure, number of effusion recurrences, number of further interventions necessary and procedurerelated complications were extracted. This information was obtained from the body of the text as well as from relevant figures. Data for survival, recurrence and further interventions were presented relative to the total number of cancer patients reported in each study. Data relating to procedure-related complications and side effects were presented relative to the total number of patients treated in each study (Tables 2-6 ). An intervention was considered to be successful if the patient survived the initial procedure and did not develop a symptomatic recurrence of their effusion and required no further pericardial interventions.
RESULTS
A search on 31 May 2013 yielded a total of 1181 papers. Titles and abstracts were reviewed for relevance. Most were retrospective cohort studies with a small number of prospective studies. Duplicates, case reports, review articles, studies superseded by later reports from the same institution and publications containing no quantitative data were excluded. Only 59 papers fulfilled these criteria and were considered further (Fig. 1) .
Single pericardiocentesis
Pericardiocentesis is indicated as an emergency procedure in patients with cardiac tamponade. Before the advent of twodimensional (2D) echocardiography, the procedure was carried out using a blind subxiphoid approach, which often resulted in serious complications [7] . Given that 2D echocardiography permits direct visualization of cardiac structures and adjacent vital organs, the procedure can now be performed with a minimal risk. Two studies reported the use of pericardiocentesis as the definitive treatment for malignant pericardial effusion [10, 11] (Table 2 ). Apodaca-Cruz et al. [10] treated a total of 100 patients and reported a success rate of 67%. Effusions recurred in the remaining patients, with 29% of patients requiring further intervention. The rate of complications was low at 3% and involved vagal hypotension in all 3 cases. Lindenberger et al. [11] reported 31 patients treated by pericardiocentesis. Symptomatic relief was achieved in only 45.2% of patients and was associated with a higher rate of procedure-related complications of 8.3%. These included arrhythmias and ventricular puncture. More than half of the patients (54.8%) required further intervention for reaccumulation of pericardial fluid. In neither study were procedure-related deaths reported.
Extended catheter drainage
To reduce the rate of effusion recurrence following pericardiocentesis, extended catheter drainage has been attempted by placement of an indwelling catheter into the pericardial space. Our search identified six studies describing the management of malignant pericardial effusion using extended catheter drainage [12] [13] [14] [15] [16] [17] (Table 3 ). Complete resolution of effusion was achieved in only 55.1% of cases. The remainder required further intervention for effusion recurrence. The rate of complications was 12%, arrhythmias being the most common. No fatalities as a direct consequence of the procedure were reported in any of the six studies.
Pericardial sclerosis
Another well-established approach to reduce the reaccumulation of pericardial fluid is the use of sclerosing agents. These are instilled into the pericardium with the intention to obliterate the potential space by causing adhesions between the pericardial layers. Twenty-two studies described the use of a variety of sclerosants to treat malignant pericardial effusion (Table 4) . Cisplatin was the most widely used agent, being reported in five studies with a total of 176 patients [18, 25, 29, 36, 38] . In 90.3% of these patients, treatment was successful with recurrence of the effusion and procedure-related morbidity in 9.1 and 13.6%, respectively. The intrapericardial instillation of tetracycline was reported in two studies totalling 91 patients with a good overall success rate of 87.9 and only 8.8% suffering effusion recurrence, but complications and side effects were high at 45.1% [21, 37] . Thiotepa (N,N 0 , N 0 -triethylenethiophosphoramide) was used in three studies totalling 75 patients [19, 20, 30] . Of those, 90.7% remained symptom free and only 6.7% suffered complications. Forty-five patients treated with bleomycin were reported in three studies [31, 33, 39] . This agent was able to prevent recurrence of effusion in 88.9% of cases, but 26.7% of patients sustained complications, most commonly fever, but in 1 case constrictive pericarditis caused death. Mitomycin C has been reported in only two studies totalling 28 participants [23, 27] . Of those, 19 (67.9%) were treated successfully, but there was 1 case of pericardial constriction (3.6%). Three studies, with a total of 27 patients, reported the use of mitoxantrone in the treatment of malignant pericardial effusion [28, 34, 35] . This agent improved clinical status in 24 patients (88.9%) with no reported complications. The remaining four studies used a range of unique agents to induce pericardial sclerosis [22, 24, 26, 32] (Table 5 ). These included two other tetracycline antibiotics [24, 26] and a second platinum-based chemotherapy, carboplatin [32] . Their results were similar to those of tetracycline and cisplatin, respectively. The final agent, OK-432 ( penicillin-killed Streptococcus pyogenes), was successful in the 3 cases treated, but unfortunately caused high fever and pain in each of these [22] .
Surgical intervention
Three surgical approaches to the treatment of malignant pericardial effusion have been described in 19 studies: pericardial fenestration, pericardiectomy and pericardio-peritoneal shunt insertion [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] (Table 5 ). Pericardial fenestration is the creation of a 'pericardial window' a few centimetres in diameter to enable the drainage of pericardial fluid into the pleural space. Pericardiectomy, the surgical resection of part or all of the pericardium, is a more aggressive approach to achieve a more complete drainage. The insertion of a pericardio-peritoneal shunt involves the placement of a Denver shunt inflow catheter into the pericardial space with the abdominal end tunnelled subcutaneously across the right costal margin through a 3-cm skin incision into the peritoneal cavity. A pumping chamber connected to the shunt is then used for intermittent compression. The most commonly reported surgical procedure in the literature is pericardial fenestration, which was described in 15 studies [40-44, 46, 48-54, 56, 58] . This technique was associated with an overall success rate of 93.3%. Recurrence was reported in 5.7% and complications occurred in 4.5%. One procedure-related death was reported. Ten of the 15 studies reported this procedure performed via the subxiphoid approach, whereby a short vertical incision is made over the xiphoid process, allowing the pericardium to be grasped with surgical clamps and incised directly [40, 41, 46, 48, 50-53, 56, 58] . This procedure had a success rate of 93.2%, an effusion recurrence rate of 5.5% and a complication rate of 3.9%. In three studies, pericardial fenestration was carried out using video-assisted thoracic surgery (VATS) [43, 44, 49, 54] . With the patient under general anaesthesia and using single-lung ventilation, a thoracoscope is introduced into the thorax. Two further ports are used to grasp and excise a portion of the pericardium to create a pericardial window. This approach was successful in 90.9% of cases, with 9.1% recurrence overall. Patients sustained complications in 4.8% of cases. In one study, 26 patients underwent pericardial fenestration by left mini-thoracotomy [42] . This achieved control of the effusion in 96.2% of cases, with only 1 patient requiring further treatment because of recurrence (3.8%) and complications observed in 11.3% of patients. Another report described the use of an alternative approach, known as mediastinoscope-controlled parasternal fenestration, to create an opening in the [10] 67/100 (67.0) Vagal hypotension (n = 3) Lindenberger et al. [11] 14/31 (45.2) Arrhythmia (n = 6), vasovagal reaction (n = 2), ventricular puncture (n = 1), breathing difficulties (n = 1) a Number of patients with malignancy. b Total number of patients treated in the study. [12] 12/22 (54.5) Cardiac injury (n = 2), pneumothorax (n = 1) Gatenby et al. [13] 3/12 (25.0) Transient ventricular arrhythmia (n = 1), hypotension (n = 1) Hingorani and
Bloomberg [14] 8/9 (88.9) Transient atrial fibrillation (n = 2), pericardial pain (n = 1), erratic drainage (n = 1) Kopecky et al. [15] 5/16 (31.3) Catheter occlusion (n = 3), infection (n = 1), bradycardia and symptomatic hypotension (n = 1) Medary et al. [16] 9/9 (100) None reported Patel et al. [17] 6/10 (60.0) None reported a Number of patients with malignancy. b Total number of patients treated in the study.
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G.M. Jama et al. / Interactive CardioVascular and Thoracic Surgerypericardium in 22 patients, with 100% success and 13.6% complications [54] . Owing to their low numbers, these single reports must be interpreted with caution. Pericardiectomy was the second most commonly reported surgical procedure [45, 47, 55] . All three studies that described this approach were performed using VATS, with success in all cases and a comparatively higher overall rate of complications of 10.3%. A single study comprising only 4 cases reported the insertion of a pericardio-peritoneal shunt to treat malignant pericardial effusion [57] . This approach was successful in each patient without reported complications, but as before, the small numbers in this series require caution in its interpretation.
Percutaneous balloon pericardiotomy
Percutaneous balloon pericardiotomy (PBP) requires a guide wire to be inserted into the pericardial space over which a balloon catheter is passed and inflated to create a window in the pericardium. Typically, fluid passes from the pericardium into the left pleural space. We identified 10 studies reporting the use of this technique to manage malignant pericardial effusion [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] ( Table 6 ). In most of these, the outcomes were good, with control of the effusion in 90.4%. The least-good outcomes were seen in the smaller studies, suggesting that PBP is best be performed in centres with a higher throughput of patients. There were no procedure-related deaths in any of the 10 studies, but complications occurred in 32%, the most common being pleural effusion, fever and pneumothorax.
DISCUSSION
Malignant pericardial effusion is an important complication of advanced malignancy that contributes significantly to morbidity [18] 23/25 (92.0) Constriction (n = 4), transient atrial fibrillation (n = 3), non-sustained ventricular tachycardia (n = 2) Lafaras et al. [25] 55/56 (98.2) Paroxysmal atrial fibrillation (n = 5) Maisch et al. [29] 36/42 (85.7) Myocardial ischaemia (n = 1) Oida et al. [36] 7/7 (100) Nausea (n = 2) Tomkowski et al. [38] 38/46 (82.6) Transient atrial fibrillation (n = 7) Tetracycline 80/91 (87.9) 41/91 (45.1) Davis et al. [21] 30/33 (90.9) Mild transient fever (n = 12), ventricular arrhythmia (n = 5), atrial fibrillation (n = 1) Shepherd et al. [37] 50/58 (82.8) Pain (n = 9), transient atrial arrhythmia (n = 5), fever (n = 5), catheter occlusion (n = 4) Thiotepa 68/75 (90.7) 5/75 (6.7) Bishiniotis et al. [19] 19/19 (100) Atrial fibrillation (n = 2), vasovagal reaction (n = 1) Colleoni et al. [20] 19/23 (82.6) Transient grade III thrombocytopenia and leukopenia (n = 1), grade I leukopenia (n = 1) Martinoni et al. [30] 30 Imamura et al. [22] 3/3 (100) High fever, chills and chest pain (n = 3)
Both bold and italic values are sums of the values from the references. Bold is intended to signify the sum of a main treatment modality, e.g. pericardial fenestration while italic signifies the sum of a sub-approach to that modality, e.g. VATS.
In cases where there is only one approach to a given treatment modality, the values are in bold, e.g. 'sclerotherapy with cisplatin' or 'percutaneous balloon pericardiotomy'. 'Overall' values at the top of tables are also in bold as a summary of each modality as a whole.
and also can hasten death. Although the prognosis of patients with this condition is considered to be poor, therapeutic intervention, if successful, can improve quality of life and prolong survival. Despite this, there have been no randomized controlled trials of therapies and practices differ widely. Immediate drainage of the pericardial cavity prevents tamponade and so relieves symptoms rapidly. Therefore, simple pericardiocentesis under local anaesthesia can provide immediate relief. It is a relatively quick and straightforward procedure that can be performed by physicians and radiologists, and provides fluid for cytological diagnosis. The use of echocardiographic guidance significantly reduces procedurerelated complications (5.9%). Despite its usefulness in the acute setting, pericardiocentesis is frequently inadequate in the medium term because of its high rate of recurrence. Even when pericardiocentesis is followed by extended tube drainage, the results are poor. Indeed, this approach had only a 55.1% success rate overall when we assessed six individual series and was associated with a higher rate of complication (12%). For this reason, in many patients, pericardiocentesis must be followed by a more definitive procedure.
The intrapericardial instillation of a sclerosant has been widely performed in cases of recurrent malignant pericardial effusion. [40] 49/51 (96.1) Myocardial injury (n = 3) Campbell et al. [41] 22/25 (88.0) Hypotension (n = 1) Lajos et al. [46] 15/15 (100) None reported Moores et al. [48] 80/82 (97.6) None reported Olson et al. [50] 18/18 (100) Lobar pneumonia (n = 2), atrial fibrillation (n = 2), fascial dehiscence (n = 1), constrictive pericarditis (n = 1), intraoperative entry into the left pleural space (n = 1) Osuch et al. [51] 6/6 (100) None reported Sarigul et al. [52] 33/41 (80.5) Cardiac arrest (n = 12), death (n = 7), pneumothorax (n = 6) Sugimoto et al. [53] 22/24 (91.7) None reported Vassilopoulos et al. [56] 26/26 (100) Ventricular tachycardia (n = 1) Wilkes et al. [58] 86/95 (90.5) Prolonged postoperative ventilation (n = 2), infection (n = 1), wound dehiscence (n = 1), death (n = 1) VATS 70/77 a (90.9) 5/104 b (4.8) Geissbuhler et al. [43] 12/12 (100) Pulmonary embolism (n = 1), CVA (n = 1), ventricular arrhythmia (n = 1) Georghiou et al. [44] 3/3 (100) Supraventricular arrhythmia (n = 1) Neragi-Miandoab et al. [49] 55 [45] 18/18 (100) Atelactasis (n = 4), pneumonia (n = 2), arrhythmia (n = 1) Mack et al. [47] 9/9 (100) None reported Uramoto et al. [55] 11/11 (100) None reported Pericardio-peritoneal shunt 4/4 (100) None reported Denver shunt Wang et al. [57] 4/4 (100) None reported Both bold and italic values are sums of the values from the references. Bold is intended to signify the sum of a main treatment modality, e.g. pericardial fenestration while italic signifies the sum of a sub-approach to that modality, e.g. VATS.
In cases where there is only one approach to a given treatment modality, the values are in bold, e.g. 'sclerotherapy with cisplatin' or 'percutaneous balloon pericardiotomy'. 'Overall' values at the top of tables are also in bold as a summary of each modality as a whole. VATS: video-assisted thoracoscopic surgery; MCPF: mediastinoscope-controlled parasternal fenestration.
a Number of patients with malignancy. b Total number of patients treated in the study.
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Overall, when considering all agents together, this approach has a success rate of 87.8%, but suffers from a high rate of morbidity (20.5%). There appears to be little difference between the individual agents in terms of their effectiveness, although cisplatin and tetracycline have been the most widely reported. The lack of availability of appropriate preparations of tetracycline and its possible higher rate of complications currently make cisplatin a more favourable agent. It might be especially useful for poor surgical candidates. Surgical decompression of the pericardium appears overall to have a higher success rate of 93.5% and to be associated with fewer complications (4.7%). The subxiphoid approach has the advantage that it can be performed under local anasthaesia in contrast to VATS, which requires general anaesthesia and single-lung [59] 8/9 (88.9) Intrapericardial balloon rupture (n = 1), right ventricular wall perforation, hypotension and bradycardia (n = 1) Di Segni et al. [60] 7/7 (100) Pain (n = 2), profuse bleeding at entry site (n = 1), bradycardia (n = 1) Galli et al. [61] 10/10 (100) None reported Jackson et al. [62] 1/2 (50.0) Pain (n = 1) Navarro Del Amo et al. [63] 4/4 (100) Mild pleural effusion (n = 4)
Ovunc et al. [64] 6/10 (60.0) Pleural effusion (n = 2) Palacios et al. [65] 8/8 (100) Pleural effusion (n = 8) Swanson et al. [66] 25/27 (92.6) Cerebrovascular accident (n = 1), pneumopericardium (n = 1) Wang et al. [67] 44/50 (88.0) Fever (n = 14), mild pneumothorax (n = 3), balloon breakage (n = 1) Ziskind et al. [68] 37/39 (94.9) Fever (n = 6), profuse bleeding (n = 1), pleural effusion requiring thoracocentesis (n = 8), mild pneumothorax (n = 2)
In cases where there is only one approach to a given treatment modality, the values are in bold, e.g. 'sclerotherapy with cisplatin' or 'percutaneous balloon pericardiotomy'. 'Overall' values at the top of tables are also in bold as a summary of each modality as a whole. ventilation, procedures that can be challenging in critically ill patients. Although surgical treatment options appear to be associated with better clinical outcomes, the lack of adequately controlled studies means that selection bias, with the healthier cases more likely to undergo surgery, remains a real possibility. The published studies reported performance status inconsistently. In only 6 of 40 papers that reported a medical-cardiological intervention was information on the performance status provided [10, 18, 20, 23, 30, 32] , whereas in only 1 of 19 surgical studies was the performance status available [55] . Given that these data include only 11 surgical cases, in contrast to 208 medical cases, statistical comparison would be invalid; however, in both groups the median performance status appeared to be equivalent to 3 using the ECOG scale. Clearly, only with true randomization will this important question be answered. PBP was developed to avoid some of the disadvantages associated with surgery, because it can be performed under local anaesthesia and, in most cases, enables early discharge home. It has a success rate of 90.4%, but is associated with more procedure-related complications (32%) when compared with conventional surgery.
Sclerosant therapy is appropriate for those unfit for any surgical intervention, but its high risk of complications suggests that an intervention that promotes pericardial drainage is the treatment of choice for most other cases. What remains unclear is which procedure is truly superior. We conclude that more and higherquality studies are necessary to address the issues that have been raised by this literature review. A head-head comparison, preferably as a randomized controlled trial comparing the two least invasive approaches, pericardial fenestration via the subxiphoid approach versus PBP, would be valuable to the field.
LIMITATIONS
Several limitations in the published literature hamper the comparison of the treatment modalities used to treat malignant pericardial effusion. First, short-term success rates are difficult to define because survival following a procedure depends significantly on the institution, the clinician and the patient. Second, metastatic pericardial disease remains a lethal condition. Prognosis is primarily dictated by the non-cardiac progression of the underlying malignancy, thereby making long-term success rates difficult to define. Third, all studies included in this review were observational studies, most of them retrospective. This is an important additional factor that limits the interpretation of observed differences between results.
